I am executingrates
I am executingpopulation
[1.0, 3.0, 129.0, 68.0, 'that estimation of fertility and  <population>  has been done within ', 17.0, 1]
[1.0, 63.0, 1028.0, 18.0, 'Education and Research, Chandigarh, India;  <Population>  and Work Ability Program ', 3.6, 1]
[1.0, 62.0, 997.0, 10.0, 'J Hoffman MA), Center for  <Translation>  Research and Implementation Science ', 3.3333333333333335, 1]
[1.0, 3.0, 150.0, 68.0, 'sources 21,22 for fertility and  <population>  estimates, which affect estimates ', 2.72, 1]
[1.0, 3.0, 165.0, 68.0, 'estimates expressed in terms of  <population>  rates. The purpose of ', 1.7, 1]
[1.0, 58.0, 1080.0, 4.0, 'Mayo Clinic Foundation for Medical  <Education>  and Research, Rochester, MN, ', 1.3333333333333333, 1]
[1.0, 58.0, 1091.0, 18.0, '(F Alahdab MD); School of  <Population>  and Global Health (K ', 1.2857142857142858, 1]
[1.0, 5.0, 124.0, 4.0, 'health states used in the  <estimation>  of non-fatal results for ', 1.0, 1]
[1.0, 45.0, 242.0, 4.0, 'Improving DivergentWorseningDirection of overall trend  <Deviation>  from equal relative change ', 1.0, 1]
[1.0, 3.0, 194.0, 68.0, 'fertility rates have to match  <population>  rate change such that ', 0.9855072463768116, 1]
[1.0, 3.0, 214.0, 68.0, 'not accounted for in our  <population>  estimates. GBD cause list ', 0.7640449438202247, 1]
[1.0, 60.0, 1063.0, 4.0, '(H Elkout PhD), World Health  <Organization>  (WHO), Geneva, Switzerland; Committee ', 0.6666666666666666, 1]
[1.0, 51.0, 249.0, 68.0, 'study is the estimation of  <population>  and fertility in the ', 0.5151515151515151, 1]
[1.0, 40.0, 40.0, 4.0, '2000 2005 2010 2017028056084011201400Age-standardised YLD  <rates>  per 100 000 people ', 0.3333333333333333, 1]
[1.0, 24.0, 297.0, 10.0, '(−1·9 to −0·6)* Asymptomatic atrial  <fibrillation>  and flutter22 545·7 (19 ', 0.3333333333333333, 1]
[1.0, 59.0, 1336.0, 4.0, 'F Norheim PhD), Department of  <Nutrition>  (M S Farvid PhD), ', 0.3076923076923077, 1]
[1.0, 44.0, 189.0, 4.0, 'in global prevalence and YLD  <rates>  per 100 000 for ', 0.26666666666666666, 1]
[1.0, 39.0, 129.0, 4.0, 'markedly between all-age and age-standardised  <rates>  for NCDs, with all-age ', 0.25, 1]
[1.0, 58.0, 1155.0, 18.0, 'Tehran, Iran; Research School of  <Population>  Health (K A Alene ', 0.23076923076923078, 1]
[1.0, 60.0, 1075.0, 4.0, 'Assessment of Medical Devices and  <Information>  Technology, Health Technology Assessment ', 0.2222222222222222, 1]
[1.0, 24.0, 315.0, 10.0, '·· ·· ·· Symptomatic atrial  <fibrillation>  and flutter15 028·5 (13 ', 0.20833333333333334, 1]
[1.0, 48.0, 580.0, 68.0, 'patterns are probably related to  <population>  growth and ageing as ', 0.20298507462686566, 1]
[1.0, 58.0, 1166.0, 18.0, 'National Centre for Epidemiology and  <Population>  Health (M Bin Sayeed ', 0.20224719101123595, 1]
[1.0, 52.0, 159.0, 4.0, 'birth defects. Adopting in-facility delivery  <estimates>  for processing clinical data ', 0.2, 1]
[1.0, 39.0, 134.0, 4.0, 'rates for NCDs, with all-age  <rates>  increasing as SDI improved ', 0.19047619047619047, 1]
[1.0, 53.0, 477.0, 68.0, 'the severities experienced in this  <population>  probably do not reflect ', 0.18528610354223432, 1]
[1.0, 4.0, 130.0, 4.0, 'processed and utilised (appendix 1  <section>  2). In the supplementary ', 0.18181818181818182, 1]
[1.0, 1.0, 499.0, 68.0, 'internally consistent GBD estimates of  <population>  and fertility, and adopting ', 0.17989417989417988, 1]
[1.0, 48.0, 632.0, 68.0, 'have not expanded proportionally to  <population>  growth or in populations ', 0.17571059431524547, 1]
[1.0, 2.0, 134.0, 4.0, 'prevalent in lower-income countries. 4  <Estimates>  reported in recent iterations ', 0.16666666666666666, 1]
[1.0, 68.0, 1106.0, 4.0, 'Ratomaharo J, K essler R.  <Evolution>  of physiological variables in ', 0.16, 1]
[1.0, 60.0, 1173.0, 18.0, 'Berlin, Berlin, Germany; School of  <Population>  and Public Health (Z ', 0.15517241379310345, 1]
[1.0, 5.0, 192.0, 10.0, 'the original disability weight. A  <simulation>  of 40 000 distinct ', 0.1388888888888889, 1]
[1.0, 3.0, 154.0, 4.0, 'and population estimates, which affect  <estimates>  throughout the GBD study, ', 0.13793103448275862, 1]
[1.0, 65.0, 1087.0, 4.0, 'Shaikh MD); Friedman School of  <Nutrition>  Science and Policy, Tufts ', 0.13793103448275862, 1]
[1.0, 53.0, 140.0, 4.0, 'a measure of opioid analgesic  <consumption>  by country and the ', 0.13333333333333333, 1]
[1.0, 52.0, 170.0, 4.0, 'maternal disorders led to lower  <estimates>  of pregnancy compli - ', 0.12903225806451613, 1]
[1.0, 48.0, 636.0, 50.0, 'to population growth or in  <populations>  where economic improvements have ', 0.1278772378516624, 1]
[1.0, 49.0, 623.0, 50.0, 'persist and possibly expand as  <populations>  age. While the efforts ', 0.12077294685990338, 1]
[1.0, 2.0, 675.0, 68.0, 'based on the GBD reference  <population>  19 unless otherwise specified. ', 0.12035398230088495, 1]
[1.0, 53.0, 682.0, 68.0, 'bias for subsets of the  <population>  that have access to ', 0.11888111888111888, 1]
[1.0, 3.0, 160.0, 4.0, 'throughout the GBD study, particularly  <estimates>  expressed in terms of ', 0.11428571428571428, 1]
[1.0, 60.0, 1215.0, 18.0, 'A Butt PhD); Department of  <Population>  and Health, Metropolitan Autonomous ', 0.11392405063291139, 1]
[1.0, 44.0, 211.0, 4.0, 'in prevalence (A) and YLD  <rates>  (B) between males and ', 0.10810810810810811, 1]
[1.0, 53.0, 147.0, 4.0, 'country and the prevalence of  <injection>  drug use. Enhancements in ', 0.10810810810810811, 1]
[1.0, 66.0, 1201.0, 18.0, 'currently a Program Analyst for  <Population>  and Development at the ', 0.10714285714285714, 1]
[1.0, 68.0, 1168.0, 9.0, 'K ositanont U, Dejsomritrutai W,  <Charoenratanakul>  S. Acute respiratory illness ', 0.10344827586206896, 1]
[1.0, 66.0, 1213.0, 18.0, 'Office of the United Nations  <Population>  Fund. Ted Miller reports ', 0.1, 1]
[1.0, 1.0, 803.0, 68.0, 'YLDs reflects an ageing global  <population>  commensurate with declines in ', 0.09970674486803519, 1]
[1.0, 49.0, 911.0, 68.0, 'health for an individual and  <population>  but also lost capital ', 0.09686609686609686, 1]
[1.0, 5.0, 662.0, 50.0, 'for 2017, excluding countries with  <populations>  of less than 1 ', 0.09225092250922509, 1]
[1.0, 6.0, 168.0, 4.0, 'including latent tuberculosis infec -  <tion>  was the third leading ', 0.08888888888888889, 1]
[1.0, 49.0, 257.0, 4.0, 'incidence rates. High age-standardised incidence  <rates>  of acute viral hepatitis ', 0.08333333333333333, 1]
[1.0, 44.0, 222.0, 4.0, 'as well as the cause  <composition>  of those differences for ', 0.08333333333333333, 1]
[1.0, 3.0, 174.0, 4.0, 'of using internally derived demographic  <estimates>  is to ensure internal ', 0.08163265306122448, 1]
[1.0, 63.0, 1250.0, 18.0, 'China (Prof S Liu PhD);  <Population>  Health Sciences, Bristol Medical ', 0.07929515418502203, 1]
[1.0, 49.0, 850.0, 50.0, 'burden will also expand as  <populations>  age, creating challenges for ', 0.078003120124805, 1]
[1.0, 54.0, 768.0, 50.0, 'grouping (ie, Māori and non-Māori  <populations>  in New Zealand) were ', 0.07727975270479134, 1]
[1.0, 38.0, 201.0, 4.0, 'top three causes of YLD  <rates>  were low back pain, ', 0.07547169811320754, 1]
[1.0, 5.0, 201.0, 6.0, 'distinct individuals is done that  <calculates>  the distribution of comorbid ', 0.07407407407407407, 1]
[1.0, 54.0, 374.0, 18.0, 'resource allocation as well as  <popular>  and political perception of ', 0.07114624505928854, 1]
[1.0, 68.0, 1138.0, 4.0, 'PJ, Chacko E, Wood-Baker RWB,  <Cates>  CJ. Influenza vaccine for ', 0.07017543859649122, 1]
[1.0, 63.0, 1286.0, 18.0, '(A Meretoja MD), School of  <Population>  and Global Health (Prof ', 0.06844106463878327, 1]
[1.0, 49.0, 268.0, 4.0, 'persisted, however, with age-standardised incidence  <rates>  of hepatitis A and ', 0.06779661016949153, 1]
[1.0, 2.0, 170.0, 4.0, 'conditions. This topic has received  <attention>  in terms of mortality ', 0.06666666666666667, 1]
[1.0, 7.0, 535.0, 4.0, '−0·3)*−1·7% (−2·4 to −1·0)* Chlamydial  <infection>  complications5261·1 (4960·3 to 5607·8)·· ', 0.06666666666666667, 1]
[1.0, 3.0, 187.0, 4.0, 'GBD estimates. That is, mortality  <rates>  and fertility rates have ', 0.06451612903225806, 1]
[1.0, 58.0, 1357.0, 18.0, 'M Aljunid PhD); Department of  <Population>  Health, Luxembourg Institute of ', 0.06428571428571428, 1]
[1.0, 54.0, 185.0, 4.0, 'reviews and model building. In  <consultation>  with our Scientific Council, ', 0.0625, 1]
[1.0, 2.0, 175.0, 4.0, 'attention in terms of mortality  <rates>  for sex-specific conditions such ', 0.06153846153846154, 1]
[1.0, 3.0, 190.0, 4.0, 'is, mortality rates and fertility  <rates>  have to match population ', 0.06153846153846154, 1]
[1.0, 54.0, 806.0, 38.0, 'within the USA or refugee  <populations>  in host countries. Conclusion ', 0.05547445255474453, 1]
[1.0, 53.0, 186.0, 4.0, 'new data showed greater subnational  <variation>  in Mexico and Brazil. ', 0.05263157894736842, 1]
[1.0, 68.0, 1198.0, 6.0, 'KL, Baken L, Nelson A.  <Relation>  between influenza vaccination and ', 0.05128205128205128, 1]
[1.0, 48.0, 325.0, 4.0, 'Between 1990 and 2017, YLD  <rates>  for females decreased for ', 0.05, 1]
[1.0, 52.0, 219.0, 4.0, 'enforced internal consistency among our  <estimates>  such that, for example, ', 0.05, 1]
[1.0, 64.0, 1293.0, 4.0, '(B O Olusanya PhD); NCD  <Prevention>  & Control Unit, Ministry ', 0.05, 1]
[1.0, 71.0, 200.0, 4.0, 'experience in the crop, technology  <adoption>  and its relationship to ', 0.05, 1]
[1.0, 5.0, 201.0, 4.0, 'distinct individuals is done that  <calculates>  the distribution of comorbid ', 0.04938271604938271, 1]
[1.0, 7.0, 557.0, 4.0, '5·2)0·7% (−3·8 to 5·2) Gonococcal  <infection>  47 269·2 (36 099·9 ', 0.04878048780487805, 1]
[1.0, 5.0, 203.0, 4.0, 'is done that calculates the  <distribution>  of comorbid con - ', 0.04819277108433735, 1]
[1.0, 71.0, 209.0, 4.0, 'to quality of life and  <migration>  processes. This type of ', 0.0449438202247191, 1]
[1.0, 5.0, 524.0, 18.0, '25 years. The GBD 2017  <Population>  and Fertility 24 analysis ', 0.04455445544554455, 1]
[1.0, 8.0, 393.0, 4.0, '(1·9 to 4·2)* Upper respiratory  <infection>  episode236 051·4 (211 015·2 ', 0.044444444444444446, 1]
[1.0, 69.0, 321.0, 4.0, 'Bank. Countries commit to strong  <action>  on human capital to ', 0.04395604395604396, 1]
[1.0, 45.0, 333.0, 4.0, 'more or increasing less. Green  <indicates>  that the overall trend ', 0.042105263157894736, 1]
[1.0, 5.0, 215.0, 4.0, 'the basis of the expected  <distribution>  of each condition’s sequelae ', 0.042105263157894736, 1]
[1.0, 1.0, 217.0, 4.0, 'a predominant focus on mortality  <rates>  as a common metric ', 0.041666666666666664, 1]
[1.0, 52.0, 285.0, 6.0, 'and strengthened the empirical re  <lationship>  with known environmental, nutritional, ', 0.0410958904109589, 1]
[1.0, 2.0, 209.0, 4.0, 'global, age- standardised, all-cause YLD  <rates>  are approximately 10% higher ', 0.04040404040404041, 1]
[1.0, 53.0, 210.0, 4.0, 'for injuries non-fatal measurement. These  <updates>  included incorporating GBD 2017 ', 0.04, 1]
[1.0, 14.0, 205.0, 4.0, '−19·3)*−16·1% (−18·5 to −13·4)* Protein-energy  <malnutrition>  96 454·6 (93 495·9 ', 0.04, 1]
[1.0, 45.0, 346.0, 4.0, 'decreasing age-standardised YLDs) and red  <indicates>  that the overall trend ', 0.037037037037037035, 1]
[1.0, 50.0, 209.0, 4.0, 'harm-reduction strategies such as opioid  <substitution>  therapy and needle programmes. ', 0.037037037037037035, 1]
[1.0, 53.0, 221.0, 4.0, 'groups and updating the differential  <equation>  solver for converting incidence ', 0.036036036036036036, 1]
[1.0, 38.0, 315.0, 6.0, 'for all causes and then  <separately>  for Level 1 causes. ', 0.03592814371257485, 1]
[1.0, 52.0, 251.0, 4.0, 'methodological changes have lowered global  <estimates>  for many of the ', 0.03571428571428571, 1]
[1.0, 67.0, 1190.0, 4.0, 'Barrionuevo-Rosas L, et al. Global  <estimates>  of human papillomavirus vaccination ', 0.03571428571428571, 1]
[1.0, 7.0, 587.0, 4.0, '3·3)1·9% (−1·3 to 5·6) Gonococcal  <infection>  complications1705·4 (1596·2 to 1824·5)·· ', 0.03571428571428571, 1]
[1.0, 67.0, 1194.0, 4.0, 'Global estimates of human papillomavirus  <vaccination>  coverage by region and ', 0.034482758620689655, 1]
[1.0, 68.0, 1198.0, 4.0, 'KL, Baken L, Nelson A.  <Relation>  between influenza vaccination and ', 0.03418803418803419, 1]
[1.0, 45.0, 358.0, 4.0, '(ie, increasing age-standardised YLDs). Yellow  <indicates>  cause-regions where one sex ', 0.03333333333333333, 1]
[1.0, 68.0, 1201.0, 4.0, 'Nelson A. Relation between influenza  <vaccination>  and outpatient visits, hospitalization, ', 0.03333333333333333, 1]
[1.0, 49.0, 332.0, 4.0, 'hepatitis C curative treatments.29–31 Incidence  <rates>  of lower respiratory infections ', 0.032520325203252036, 1]
[1.0, 24.0, 390.0, 4.0, '·· ·· ·· ·· Symptomatic  <claudication>  due to peripheral arterial ', 0.032520325203252036, 1]
[1.0, 61.0, 1371.0, 10.0, 'Foigt PhD); Gene Expression &  <Regulation>  Program, Cancer Institute, Philadelphia, ', 0.032362459546925564, 1]
[1.0, 5.0, 245.0, 4.0, 'change from GBD 2016. YLD  <computation>  YLDs were estimated as ', 0.032, 1]
[1.0, 48.0, 371.0, 4.0, '1990 and 2007, the YLD  <rates>  for males decreased for ', 0.031746031746031744, 1]
[1.0, 51.0, 247.0, 4.0, 'this year’s study is the  <estimation>  of population and fertility ', 0.03076923076923077, 1]
[1.0, 4.0, 242.0, 4.0, 'non-fatal disease and injury outcomes.  <Estimation>  occurred at the five ', 0.029850746268656716, 1]
[1.0, 52.0, 276.0, 4.0, 'the unexplained geo - graphical  <variation>  in disease incidence, and ', 0.029197080291970802, 1]
[1.0, 53.0, 457.0, 10.0, 'severity distributions that affect YLD  <calculation>  using the Medical Expenditure ', 0.02881844380403458, 1]
[1.0, 1.0, 471.0, 10.0, 'estimation methods including updating the  <calculation>  of the Socio-demographic Index ', 0.02857142857142857, 1]
[1.0, 5.0, 261.0, 4.0, 'a disability weight for health  <states>  of each mutually exclusive ', 0.028368794326241134, 1]
[1.0, 54.0, 262.0, 4.0, 'necessary part of the study’s  <estimation>  and reporting process, but ', 0.028368794326241134, 1]
[1.0, 4.0, 251.0, 4.0, 'five levels of the GBD  <location>  hierarchy—global, super-regional, regional, national, ', 0.027972027972027972, 1]
[1.0, 38.0, 295.0, 4.0, 'the all-age and age-standardised YLD  <rates>  by SDI and GBD ', 0.027210884353741496, 1]
[1.0, 49.0, 663.0, 12.0, 'of cardiovascular disease in these  <popu>  lations still remains high, ', 0.02643171806167401, 1]
[1.0, 3.0, 508.0, 10.0, 'non-fatal estimation begins with the  <compilation>  of data sources from ', 0.02610966057441253, 1]
[1.0, 52.0, 301.0, 4.0, 'con - ditions. For nutri  <tional>  deficiencies, we extended our ', 0.024691358024691357, 1]
[1.0, 53.0, 278.0, 4.0, 'falls 88 that required medical  <attention>  per year—a difference that ', 0.023809523809523808, 1]
[1.0, 52.0, 309.0, 4.0, 'extended our analysis of protein-energy  <malnutrition>  past age 5 years, ', 0.023529411764705882, 1]
[1.0, 5.0, 291.0, 4.0, 'from conditions that lack specific  <estimation>  models. Uncertainty analysis We ', 0.023391812865497075, 1]
[1.0, 51.0, 294.0, 4.0, 'more detail in the Limitations  <section>  below. Other notable cause-specific ', 0.022598870056497175, 1]
[1.0, 66.0, 1219.0, 4.0, 'Fund. Ted Miller reports an  <evaluation>  contract from AB InBev ', 0.021505376344086023, 1]
[1.0, 3.0, 312.0, 4.0, '4 causes. We also report  <estimates>  for 3484 sequelae, nine ', 0.0213903743315508, 1]
[1.0, 6.0, 310.0, 4.0, 'a decrease in age-standardised incidence  <rates>  of upper respiratory infections ', 0.0213903743315508, 1]
[1.0, 49.0, 726.0, 11.0, 'burden, investing in health system  <infrastructure>  to ensure access to ', 0.02127659574468085, 1]
[1.0, 5.0, 601.0, 10.0, 'including under-5 mortality rates (Pearson’s  <correlation>  coefficient r=0·873), and results ', 0.02079002079002079, 1]
[1.0, 5.0, 313.0, 4.0, 'GBD study design. 19,24,25 The  <distribution>  of every step in ', 0.02072538860103627, 1]
[1.0, 48.0, 733.0, 10.0, 'also concerning given the former’s  <relation>  with self-harm and the ', 0.020491803278688523, 1]
[1.0, 2.0, 306.0, 4.0, 'on an annual basis, new  <estimates>  are provided not only ', 0.02040816326530612, 1]
[1.0, 53.0, 307.0, 4.0, 'falls. The WHO and GBD  <estimates>  on road injuries were ', 0.02030456852791878, 1]
[1.0, 48.0, 739.0, 10.0, 'with self-harm and the latter’s  <relation>  with potential loss of ', 0.020242914979757085, 1]
[1.0, 4.0, 307.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). Custom models were ', 0.020100502512562814, 1]
[1.0, 5.0, 319.0, 4.0, 'of every step in the  <computation>  process is stored in ', 0.020100502512562814, 1]
[1.0, 2.0, 313.0, 4.0, 'provided not only for new  <estimation>  years but also for ', 0.019704433497536946, 1]
[1.0, 52.0, 343.0, 4.0, 'in the number of protein-energy  <malnutrition>  cases, it instead reflects ', 0.0196078431372549, 1]
[1.0, 1.0, 329.0, 4.0, 'the study have increased the  <estimation>  detail for conditions, locations, ', 0.019230769230769232, 1]
[1.0, 2.0, 320.0, 4.0, 'but also for all previous  <estimation>  years and supersede any ', 0.01904761904761905, 1]
[1.0, 51.0, 327.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). Cause-specific considerations, comparisons, ', 0.01904761904761905, 1]
[1.0, 57.0, 1224.0, 4.0, 'Center (A Kasaeian PhD), Knowledge  <Utilization>  Research Center (Prof R ', 0.01904761904761905, 1]
[1.0, 50.0, 315.0, 4.0, 'among other causes. Figure 6  <illustrates>  how divergent trends were ', 0.018691588785046728, 1]
[1.0, 52.0, 354.0, 4.0, 'more comprehensive assessment of acute  <malnutrition>  than was estimated previously. ', 0.018604651162790697, 1]
[1.0, 49.0, 426.0, 4.0, 'health loss after upper respiratory  <infection>  among all ages, with ', 0.018433179723502304, 1]
[1.0, 54.0, 340.0, 4.0, 'leading causes, respectively. A different  <aggregation>  or level of detail ', 0.0182648401826484, 1]
[1.0, 60.0, 1279.0, 4.0, 'PhD), Institute for Research and  <Innovation>  in Health (J Das ', 0.018018018018018018, 1]
[1.0, 2.0, 333.0, 4.0, 'year’s study on non-fatal burden  <incorporates>  improvements in study design, ', 0.017937219730941704, 1]
[1.0, 51.0, 340.0, 4.0, 'GBD 2017, we added the  <Malnutrition>  and Enteric Disease (MAL-ED) ', 0.017937219730941704, 1]
[1.0, 6.0, 351.0, 4.0, '000, and in age-standardised incident  <rates>  of oral disorders of ', 0.017543859649122806, 1]
[1.0, 2.0, 338.0, 4.0, 'incorporates improvements in study design,  <estimation>  strategy, and data availability, ', 0.017543859649122806, 1]
[1.0, 54.0, 806.0, 12.0, 'within the USA or refugee  <populations>  in host countries. Conclusion ', 0.017518248175182483, 1]
[1.0, 1.0, 357.0, 4.0, 'from 1990 to 2017 and  <updates>  results from previous GBD ', 0.01694915254237288, 1]
[1.0, 53.0, 347.0, 4.0, 'and GBD 2017 had similar  <estimates>  when comparisons were available—for ', 0.016877637130801686, 1]
[1.0, 5.0, 714.0, 10.0, 'and results from the SDI  <calculation>  are available in the ', 0.016835016835016835, 1]
[1.0, 5.0, 363.0, 4.0, 'distributions and disability weights. Final  <estimates>  are computed using the ', 0.01646090534979424, 1]
[1.0, 52.0, 387.0, 4.0, 'estimated and reported separately. The  <estimation>  strategy for diabetes is ', 0.016129032258064516, 1]
[1.0, 60.0, 1305.0, 4.0, 'Institute on Deafness and Other  <Communication>  Disorders (H J Hoffman ', 0.016129032258064516, 1]
[1.0, 54.0, 370.0, 4.0, 'of health policy and resource  <allocation>  as well as popular ', 0.01606425702811245, 1]
[1.0, 62.0, 1249.0, 4.0, 'Institute for Physical Activity and  <Nutrition>  (S Islam PhD), School ', 0.01606425702811245, 1]
[1.0, 4.0, 358.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). Prevalence was estimated ', 0.016, 1]
[1.0, 49.0, 460.0, 4.0, 'GBD regions, with the lowest  <rates>  in Australasia and the ', 0.01593625498007968, 1]
[1.0, 48.0, 499.0, 4.0, '(20·6 to 32·5), whereas the  <rates>  for headache disorders and ', 0.015748031496062992, 1]
[1.0, 3.0, 379.0, 4.0, 'list allows for more detailed  <evaluation>  of aetiologies and outcomes ', 0.015748031496062992, 1]
[1.0, 54.0, 377.0, 4.0, 'well as popular and political  <perception>  of what causes death ', 0.015625, 1]
[1.0, 49.0, 466.0, 4.0, 'in Australasia and the highest  <rates>  in Oceania (appendix 2). ', 0.01556420233463035, 1]
[1.0, 39.0, 373.0, 4.0, '1990 and 2017, all-age YLD  <rates>  increased for females and ', 0.015384615384615385, 1]
[1.0, 50.0, 363.0, 4.0, 'greater improvements in age-standardised YLD  <rates>  than did the cause-regions ', 0.015267175572519083, 1]
[1.0, 51.0, 379.0, 4.0, 'attributions. Our overall diarrhoea incidence  <estimates>  were not affected. The ', 0.015267175572519083, 1]
[1.0, 54.0, 909.0, 12.0, 'difficulties in caring for older  <popu>  - lations suffering from ', 0.015228426395939087, 1]
[1.0, 52.0, 402.0, 4.0, 'the supplementary methods (appendix 1  <section>  4), but in summary, ', 0.015209125475285171, 1]
[1.0, 60.0, 1321.0, 4.0, 'Colombia; Epidemiology and Public Health  <Evaluation>  Group (C A Castañeda-Orjuela ', 0.015151515151515152, 1]
[1.0, 49.0, 886.0, 10.0, 'requirements these conditions—in iso -  <lation>  or as comorbidities—demand from ', 0.014771048744460856, 1]
[1.0, 57.0, 1288.0, 4.0, 'MD), Iranian National Center for  <Addiction>  Studies (Prof A Rahimi-Movaghar ', 0.014598540145985401, 1]
[1.0, 48.0, 520.0, 4.0, 'While age-standardised all-cause global YLD  <rates>  decreased by less than ', 0.014545454545454545, 1]
[1.0, 52.0, 417.0, 4.0, 'type 1 diabetes. We subtracted  <estimates>  of type 1 from ', 0.014388489208633094, 1]
[1.0, 45.0, 524.0, 4.0, 'cases and all-age and age-standardised  <rates>  for each sex Causes ', 0.013986013986013986, 1]
[1.0, 5.0, 407.0, 4.0, 'is a summary measure that  <estimates>  a location’s position on ', 0.013937282229965157, 1]
[1.0, 52.0, 426.0, 4.0, 'from overall diabetes to produce  <estimates>  for type 2 diabetes. ', 0.013937282229965157, 1]
[1.0, 5.0, 410.0, 4.0, 'measure that estimates a location’s  <position>  on a spectrum of ', 0.013793103448275862, 1]
[1.0, 53.0, 404.0, 4.0, 'for each Level 1 location-cause  <combination>  in the GBD study. ', 0.013605442176870748, 1]
[1.0, 50.0, 398.0, 4.0, 'Africa, the age- standardised YLD  <rates>  for females increased by ', 0.013468013468013467, 1]
[1.0, 1.0, 576.0, 6.0, 'admission per-capita estimates to more  <accurately>  measure the denominator for ', 0.013186813186813187, 1]
[1.0, 49.0, 664.0, 6.0, 'cardiovascular disease in these popu  <lations>  still remains high, which ', 0.013186813186813187, 1]
[1.0, 2.0, 415.0, 4.0, 'aims to use all accessible  <information>  on disease occurrence, natural ', 0.013114754098360656, 1]
[1.0, 63.0, 1329.0, 4.0, 'Lorkowski PhD); Competence Cluster for  <Nutrition>  and Cardiovascular Health (NUTRICARD), ', 0.013071895424836602, 1]
[1.0, 50.0, 408.0, 4.0, '30·0% (95% UI 6·8–68·1), while  <rates>  for males decreased by ', 0.013029315960912053, 1]
[1.0, 4.0, 418.0, 4.0, 'were used for each impairment  <estimation>  process; these details are ', 0.012903225806451613, 1]
[1.0, 52.0, 452.0, 4.0, 'adults do not make a  <distinction>  between cases of type ', 0.012779552715654952, 1]
[1.0, 48.0, 561.0, 4.0, 'of substantial improvement in age-standardised  <rates>  over time as well ', 0.012658227848101266, 1]
[1.0, 39.0, 433.0, 4.0, '3 causes of age-standardised YLD  <rates>  by location for both ', 0.0125, 1]
[1.0, 49.0, 530.0, 4.0, 'studies due to their substantial  <contribution>  to non-fatal health loss, ', 0.012461059190031152, 1]
[1.0, 4.0, 430.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). Severity distributions and ', 0.012422360248447204, 1]
[1.0, 39.0, 435.0, 4.0, 'of age-standardised YLD rates by  <location>  for both sexes combined, ', 0.012422360248447204, 1]
[1.0, 57.0, 1340.0, 4.0, 'MD), Hematology-Oncology and Stem Cell  <Transplantation>  Research Center (A Kasaeian ', 0.012269938650306749, 1]
[1.0, 2.0, 441.0, 4.0, 'comparability of data, despite different  <collection>  methods or case definitions; ', 0.012084592145015106, 1]
[1.0, 1.0, 703.0, 7.0, 'salmonella; myelodysplastic, myeloproliferative, and other  <haemopoietic>  neoplasms; subarachnoid haemorrhage; non-rheumatic ', 0.012027491408934709, 1]
[1.0, 39.0, 449.0, 4.0, 'COPD=chronic obstructive pulmonary disease. FSM=Federated  <States>  of Micronesia. Isl=Islands. LCA=Saint ', 0.011904761904761904, 1]
[1.0, 50.0, 437.0, 4.0, 'extensive knowledge of treatment and  <prevention>  methods for HIV /AIDS ', 0.011904761904761904, 1]
[1.0, 1.0, 458.0, 4.0, 'sources being used in the  <estimation>  process for GBD 2017 ', 0.011869436201780416, 1]
[1.0, 4.0, 447.0, 4.0, 'of proportions that represent the  <distribution>  of cases of a ', 0.011799410029498525, 1]
[1.0, 2.0, 452.0, 4.0, 'find a consistent set of  <estimates>  between data on prevalence, ', 0.011695906432748537, 1]
[1.0, 6.0, 466.0, 4.0, 'YLD rate, while age-standardised YLD  <rates>  decreased from 11 310 ', 0.011661807580174927, 1]
[1.0, 1.0, 466.0, 4.0, 'GBD 2017 . We improved  <estimation>  methods including updating the ', 0.011594202898550725, 1]
[1.0, 54.0, 468.0, 4.0, 'and data that inform YLD  <estimation>  in the GBD study ', 0.011527377521613832, 1]
[1.0, 2.0, 465.0, 4.0, 'of death; and to predict  <estimates>  for locations and causes ', 0.011267605633802818, 1]
[1.0, 5.0, 478.0, 4.0, 'minima and maxima over the  <estimation>  period to set the ', 0.0111731843575419, 1]
[1.0, 53.0, 470.0, 4.0, 'the USA. This poses a  <limitation>  as the severities experienced ', 0.011111111111111112, 1]
[1.0, 39.0, 474.0, 4.0, '3: Trends of age-standardised YLD  <rates>  per 100 000 for ', 0.0110803324099723, 1]
[1.0, 51.0, 481.0, 4.0, 'the Maternal and Child Epidemiology  <Estimation>  (MCEE). The MCEE methodology ', 0.01098901098901099, 1]
[1.0, 2.0, 477.0, 4.0, 'or absent data by borrowing  <information>  from other locations and ', 0.010899182561307902, 1]
[1.0, 48.0, 613.0, 4.0, 'YLD increases, even when age-standardised  <rates>  are slightly improving, might ', 0.010869565217391304, 1]
[1.0, 49.0, 582.0, 4.0, 'appendix 2). GBD risk factor  <estimates>  show that the drivers ', 0.010723860589812333, 1]
[1.0, 42.0, 411.0, 4.0, 'years, males have greater YLD  <rates>  than females, driven largely ', 0.010666666666666666, 1]
[1.0, 1.0, 497.0, 4.0, 'females, using internally consistent GBD  <estimates>  of population and fertility, ', 0.010638297872340425, 1]
[1.0, 2.0, 487.0, 4.0, 'covariates. The study conducts annual  <updates>  to incorporate new causes ', 0.010610079575596816, 1]
[1.0, 3.0, 504.0, 4.0, 'sources The process for non-fatal  <estimation>  begins with the compilation ', 0.010554089709762533, 1]
[1.0, 42.0, 418.0, 4.0, 'females, driven largely by higher  <rates>  of nutritional deficiencies. From ', 0.010471204188481676, 1]
[1.0, 39.0, 498.0, 4.0, 'by SDI quintile, 1990–2017 Mean  <estimates>  are shown. SDI=Socio-demographic Index. ', 0.01038961038961039, 1]
[1.0, 42.0, 433.0, 4.0, 'females have greater overall YLD  <rates>  in every age group. ', 0.010075566750629723, 1]
[1.0, 69.0, 629.0, 4.0, 'of childhood pneumonia in 2010:  <estimates>  of incidence, severe morbidity, ', 0.010025062656641603, 1]
[1.0, 54.0, 532.0, 4.0, 'updated data sources for older  <estimation>  years but also to ', 0.009732360097323601, 1]
[1.0, 5.0, 532.0, 4.0, '24 analysis of age-specific fertility  <rates>  revealed that through the ', 0.009708737864077669, 1]
[1.0, 42.0, 448.0, 4.0, 'year, females experience higher YLD  <rates>  due to neoplasms and ', 0.009708737864077669, 1]
[1.0, 51.0, 534.0, 4.0, 'LRI-specific summary exposure values as  <covariates>  in our models, which ', 0.009592326139088728, 1]
[1.0, 49.0, 630.0, 4.0, 'While the efforts of primary  <prevention>  approaches such as statin ', 0.009501187648456057, 1]
[1.0, 54.0, 543.0, 4.0, 'sources for the most recent  <estimation>  year. This necessitates data ', 0.009478672985781991, 1]
[1.0, 1.0, 545.0, 4.0, 'hepatitis, we added case fatality  <rates>  and hepatitis B vaccine ', 0.009433962264150943, 1]
[1.0, 54.0, 546.0, 4.0, 'most recent estimation year. This  <necessitates>  data inclusion immediately af ', 0.009411764705882352, 1]
[1.0, 51.0, 543.0, 4.0, 'which include location-specific and year-specific  <estimates>  of risk factors associated ', 0.009389671361502348, 1]
[1.0, 6.0, 550.0, 4.0, '13·6% (9·15–19·2), and the YLD  <rates>  from CMNN causes decreased ', 0.00936768149882904, 1]
[1.0, 42.0, 463.0, 4.0, 'male infants experience higher YLD  <rates>  due to nutritional deficiencies ', 0.00936768149882904, 1]
[1.0, 5.0, 548.0, 4.0, 'a decline in age-specific fertility  <rates>  over the age of ', 0.009345794392523364, 1]
[1.0, 49.0, 638.0, 4.0, 'as statin therapy and smoking  <cessation>  are evident in the ', 0.009324009324009324, 1]
[1.0, 69.0, 660.0, 4.0, 'Puckett R, Peerapatanapokin W .  <Updates>  to the Spectrum/Estimations and ', 0.009302325581395349, 1]
[1.0, 52.0, 573.0, 4.0, 'the Younossi study, with higher  <rates>  in North America and ', 0.009216589861751152, 1]
[1.0, 51.0, 556.0, 4.0, 'LRI. We observed that these  <covariates>  had significant relationships with ', 0.009111617312072893, 1]
[1.0, 5.0, 565.0, 4.0, 'U-shaped pattern; however, age-specific fertility  <rates>  in ages 10–14 years, ', 0.008988764044943821, 1]
[1.0, 52.0, 584.0, 4.0, 'Middle East, corresponding to higher  <rates>  of obesity. Cardiovascular diseases ', 0.008988764044943821, 1]
[1.0, 1.0, 567.0, 4.0, 'causes, we added in-facility delivery  <rates>  to the inpatient admission ', 0.008968609865470852, 1]
[1.0, 51.0, 565.0, 4.0, 'with diarrhoea and LRI incidence  <rates>  and therefore strengthened our ', 0.008928571428571428, 1]
[1.0, 48.0, 694.0, 4.0, 'five YLDs globally. This substantial  <portion>  of global YLDs might ', 0.008908685968819599, 1]
[1.0, 1.0, 573.0, 4.0, 'to the inpatient admission per-capita  <estimates>  to more accurately measure ', 0.008849557522123894, 1]
[1.0, 42.0, 720.0, 6.0, 'YLDs for females and males  <separately>  for 1990, 2007, and ', 0.008771929824561403, 1]
[1.0, 2.0, 571.0, 4.0, 'or sequelae, to establish the  <proportion>  of prevalent cases experiencing ', 0.008676789587852495, 1]
[1.0, 53.0, 572.0, 4.0, 'is unlikely to provide improved  <estimates>  in the near future. ', 0.008658008658008658, 1]
[1.0, 69.0, 693.0, 4.0, 'Ciaranello A, et al. Improving  <estimates>  of children living with ', 0.008639308855291577, 1]
[1.0, 54.0, 585.0, 4.0, 'a lag period between data  <collection>  and publication. One solution ', 0.008620689655172414, 1]
[1.0, 42.0, 504.0, 4.0, 'diseases. Males experience higher YLD  <rates>  due to unintentional injuries, ', 0.008547008547008548, 1]
[1.0, 54.0, 589.0, 4.0, 'data collection and publication. One  <solution>  to this challenge would ', 0.008547008547008548, 1]
[1.0, 51.0, 586.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). For HIV /AIDS, ', 0.008528784648187633, 1]
[1.0, 5.0, 599.0, 4.0, 'mortality measures including under-5 mortality  <rates>  (Pearson’s correlation coefficient r=0·873), ', 0.008350730688935281, 1]
[1.0, 53.0, 589.0, 4.0, 'between administrative records with diagnostic  <information>  and health surveys using ', 0.008350730688935281, 1]
[1.0, 1.0, 602.0, 4.0, 'ratios directly to cause-specific mortality  <rates>  to estimate incidence, and ', 0.008316008316008316, 1]
[1.0, 49.0, 690.0, 4.0, 'as percutaneous coronary intervention, coronary  <artery>  bypass grafting, and rapid ', 0.008316008316008316, 1]
[1.0, 52.0, 622.0, 4.0, 'of heart failure. The overarching  <limitation>  in cardiovascular estimation is ', 0.008281573498964804, 1]
[1.0, 37.0, 648.0, 4.0, 'to 31·1)* Nature of injury  <aggregates>  Amputations 371 422·5 (343 ', 0.008247422680412371, 1]
[1.0, 52.0, 625.0, 4.0, 'The overarching limitation in cardiovascular  <estimation>  is that low-income and ', 0.00823045267489712, 1]
[1.0, 49.0, 703.0, 4.0, '37–40 as well as secondary  <prevention>  with statins, anti - ', 0.008097165991902834, 1]
[1.0, 2.0, 607.0, 4.0, 'Presented below is a high-level  <description>  of our study methods; ', 0.008048289738430584, 1]
[1.0, 3.0, 629.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). This search process ', 0.007936507936507936, 1]
[1.0, 1.0, 627.0, 4.0, 'abuse disorders, we adopted new  <covariates>  for opioid use and ', 0.007905138339920948, 1]
[1.0, 2.0, 617.0, 4.0, 'the supplementary methods (appendix 1  <section>  4) provide further detail ', 0.007889546351084813, 1]
[1.0, 42.0, 545.0, 4.0, 'interpersonal violence, females experience higher  <rates>  than males until age ', 0.007858546168958742, 1]
[1.0, 54.0, 635.0, 4.0, 'study’s ability to produce accurate  <estimates>  in the more recent ', 0.007782101167315175, 1]
[1.0, 52.0, 654.0, 4.0, 'diagnostics. This also limits the  <identification>  of preclinical atherosclerotic disease ', 0.007766990291262136, 1]
[1.0, 50.0, 619.0, 4.0, '(COPD), where the higher COPD  <rates>  in males are probably ', 0.007722007722007722, 1]
[1.0, 4.0, 626.0, 4.0, 'of site-years for each location-year  <combination>  for each Level 1 ', 0.007722007722007722, 1]
[1.0, 51.0, 636.0, 4.0, 'inputs of antiretroviral therapy coverage  <distribution>  informed by data from ', 0.007707129094412331, 1]
[1.0, 53.0, 629.0, 4.0, 'comorbid conditions. This is a  <limitation>  because comorbidity distributions are ', 0.007707129094412331, 1]
[1.0, 54.0, 640.0, 4.0, 'estimates in the more recent  <estimation>  years. Relying more heavily ', 0.007707129094412331, 1]
[1.0, 54.0, 911.0, 6.0, 'caring for older popu -  <lations>  suffering from complex conditions ', 0.007594936708860759, 1]
[1.0, 50.0, 628.0, 4.0, 'probably due to historically higher  <rates>  of smoking compared with ', 0.007590132827324478, 1]
[1.0, 48.0, 773.0, 4.0, 'type 2 diabetes separately. Our  <estimates>  illustrate the emergence of ', 0.007575757575757576, 1]
[1.0, 42.0, 565.0, 4.0, 'Males also experience higher YLD  <rates>  from neoplasms, cardio - ', 0.007561436672967864, 1]
[1.0, 49.0, 738.0, 4.0, 'as well as to primary  <prevention>  therapeutics could help to ', 0.007561436672967864, 1]
[1.0, 5.0, 654.0, 4.0, 'were then computed using country-level  <estimates>  of SDI for 2017, ', 0.00749063670411985, 1]
[1.0, 2.0, 658.0, 4.0, 'Statistical code used for GBD  <estimation>  is publicly available online ', 0.0072992700729927005, 1]
[1.0, 2.0, 665.0, 4.0, 'publicly available online . All  <rates>  are expressed as age-standardised ', 0.007207207207207207, 1]
[1.0, 51.0, 675.0, 4.0, 'model fit to the sex  <ratio>  of prevalence observed in ', 0.007168458781362007, 1]
[1.0, 38.0, 707.0, 4.0, 'than 50. G6PD=glucose-6-phosphate dehydrogenase. GFR=glomerular  <filtration>  rate. H influenzae= Haemophilus ', 0.007155635062611807, 1]
[1.0, 53.0, 676.0, 4.0, 'Clinical data records have known  <selection>  bias for subsets of ', 0.007067137809187279, 1]
[1.0, 54.0, 694.0, 4.0, 'USA. 93 In the next  <iteration>  of the GBD study, ', 0.006980802792321117, 1]
[1.0, 52.0, 717.0, 4.0, 'haemorrhage, and subarachnoid haemorrhage. Future  <incorporation>  of more clinical record ', 0.006920415224913495, 1]
[1.0, 51.0, 697.0, 4.0, 'UNAIDS 2017 values, with some  <variation>  at the national level. ', 0.006896551724137931, 1]
[1.0, 2.0, 691.0, 4.0, 'for Accurate and Transparent Health  <Estimates>  Reporting (GATHER) 20 recommendations ', 0.0068846815834767644, 1]
[1.0, 49.0, 790.0, 4.0, 'as smoking and indoor air  <pollution>  and similarly pose challenges ', 0.0068846815834767644, 1]
[1.0, 42.0, 620.0, 4.0, 'and 2017 . Each region–cause  <combination>  shows which sex has ', 0.00684931506849315, 1]
[1.0, 54.0, 705.0, 4.0, 'plan to incorporate improved age-time  <estimation>  using a new tool, ', 0.00684931506849315, 1]
[1.0, 51.0, 702.0, 4.0, 'variation at the national level.  <Estimates>  in recent years are ', 0.006837606837606838, 1]
[1.0, 3.0, 713.0, 4.0, 'were then combined in the  <estimation>  process. The supplementary methods ', 0.006802721088435374, 1]
[1.0, 3.0, 718.0, 4.0, 'estimation process. The supplementary methods  <section>  provides further details on ', 0.006745362563237774, 1]
[1.0, 1.0, 718.0, 4.0, 'aortic and degenerative mitral subtypes;  <aggregates>  of vision disorders and ', 0.006700167504187605, 1]
[1.0, 38.0, 747.0, 4.0, 'in HIV positive cases. ‡Incidence  <estimates>  for stroke represent first-ever ', 0.00667779632721202, 1]
[1.0, 3.0, 728.0, 4.0, 'gold standard data sources, adjustments,  <correction>  factors, and standardisations employed ', 0.006633499170812604, 1]
[1.0, 5.0, 723.0, 4.0, 'the supplementary methods (appendix 1  <section>  2). Role of the ', 0.006633499170812604, 1]
[1.0, 50.0, 705.0, 4.0, 'sex-specific burden estimation. While YLD  <rates>  are highest in older ', 0.006622516556291391, 1]
[1.0, 52.0, 748.0, 4.0, 'data sources that had lower  <estimates>  than the International Study ', 0.006568144499178982, 1]
[1.0, 54.0, 730.0, 4.0, 'will address the age-time measurement  <limitation>  described above. We plan ', 0.006568144499178982, 1]
[1.0, 1.0, 734.0, 4.0, 'poisoning by other means; and  <estimates>  for natures of injury ', 0.0065252854812398045, 1]
[1.0, 51.0, 732.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). The hepatitis estimation ', 0.0065040650406504065, 1]
[1.0, 51.0, 736.0, 4.0, '1 section 4). The hepatitis  <estimation>  process has changed to ', 0.006462035541195477, 1]
[1.0, 3.0, 745.0, 4.0, 'of non-fatal data (appendix 1  <section>  4). In addition to ', 0.0064516129032258064, 1]
[1.0, 54.0, 743.0, 4.0, 'and refining our cause and  <location>  hierarchies including the causes ', 0.006430868167202572, 1]
[1.0, 3.0, 748.0, 4.0, '(appendix 1 section 4). In  <addition>  to data sources based ', 0.006420545746388443, 1]
[1.0, 38.0, 774.0, 4.0, 'percentage change of age-standardised YLD  <rates>  for 1990–2007 and 2007–17 ', 0.006389776357827476, 1]
[1.0, 51.0, 748.0, 4.0, 'consistency between mortality and non-fatal  <estimates>  for GBD 2017 . ', 0.006339144215530904, 1]
[1.0, 2.0, 745.0, 4.0, 'and continues to provide subnational  <estimates>  for countries that were ', 0.006299212598425197, 1]
[1.0, 54.0, 756.0, 4.0, 'is the first year that  <estimates>  for a non-geo - ', 0.006299212598425197, 1]
[1.0, 51.0, 757.0, 4.0, '. First, we included case-fatality  <rates>  from clinical data in ', 0.00625, 1]
[1.0, 52.0, 784.0, 4.0, 'physician-diagnosed asthma without an additional  <question>  on wheezing changed between ', 0.006201550387596899, 1]
[1.0, 2.0, 756.0, 4.0, 'in previous cycles. S ubnational  <estimation>  in GBD 2017 includes ', 0.006191950464396285, 1]
[1.0, 51.0, 768.0, 4.0, 'mortality models to improve the  <distribution>  of hepatitis deaths by ', 0.006144393241167435, 1]
[1.0, 42.0, 692.0, 4.0, 'was 0·433 for the mean  <deviation>  of female-favourable causes and ', 0.006097560975609756, 1]
[1.0, 5.0, 780.0, 4.0, 'prevalence, incidence, and YLDs Non-fatal  <estimates>  by cause for 354 ', 0.006060606060606061, 1]
[1.0, 48.0, 906.0, 4.0, 'the first year of GBD  <estimation>  for non- alcoholic fatty ', 0.006051437216338881, 1]
[1.0, 42.0, 701.0, 4.0, 'and 0·313 for the mean  <deviation>  of male-favourable causes. Figure ', 0.006015037593984963, 1]
[1.0, 52.0, 806.0, 4.0, 'conditions For dementia, we added  <covariates>  for whether studies had ', 0.005997001499250375, 1]
[1.0, 54.0, 792.0, 4.0, 'burden in groups within a  <location>  not strictly determined by ', 0.005961251862891207, 1]
[1.0, 54.0, 823.0, 4.0, 'in 2017 represents a complex  <culmination>  of nearly three decades ', 0.005698005698005698, 1]
[1.0, 5.0, 823.0, 4.0, 'interactively through an online data  <visualisation>  tool. Figure 1 shows ', 0.005689900426742532, 1]
[1.0, 53.0, 814.0, 4.0, 'data will not only inform  <estimates>  in terms of incidence ', 0.005681818181818182, 1]
[1.0, 50.0, 806.0, 4.0, 'non-fatal burden. Second, a disabling  <condition>  that occurs during this ', 0.005673758865248227, 1]
[1.0, 2.0, 817.0, 4.0, 'the first level of administrative  <organisation>  within each country except ', 0.005657708628005658, 1]
[1.0, 52.0, 847.0, 4.0, 'because only a very small  <fraction>  of studies used the ', 0.005649717514124294, 1]
[1.0, 52.0, 859.0, 4.0, 'We do not have reliable  <covariates>  for prevalence or incidence ', 0.005555555555555556, 1]
[1.0, 53.0, 834.0, 4.0, 'accurate parameters that affect GBD  <estimates>  in other modelling steps. ', 0.0055248618784530384, 1]
[1.0, 54.0, 846.0, 4.0, 'populations. This study provides comprehensive  <updates>  from prior GBD studies ', 0.005517241379310344, 1]
[1.0, 2.0, 842.0, 4.0, 'local government authorities). All subnational  <estimates>  for these countries were ', 0.00546448087431694, 1]
[1.0, 6.0, 861.0, 4.0, 'disorders (14·3%, 13·1–15·6). Figure 2  <illustrates>  the leading Level 3 ', 0.005420054200542005, 1]
[1.0, 2.0, 852.0, 4.0, 'incorporated into model development and  <evaluation>  as part of GBD ', 0.005390835579514825, 1]
[1.0, 51.0, 860.0, 4.0, 'rather than in the prevalence  <estimates>  for acute hepatitis B ', 0.005383580080753701, 1]
[1.0, 3.0, 869.0, 4.0, 'of admissions that inform GBD  <estimation>  to more than 2·6 ', 0.005376344086021506, 1]
[1.0, 6.0, 869.0, 4.0, 'Level 3 causes of YLD  <rates>  by GBD country and ', 0.005361930294906166, 1]
[1.0, 53.0, 861.0, 4.0, 'all the available data and  <covariates>  with hierarchical random effects ', 0.005326231691078562, 1]
[1.0, 2.0, 866.0, 4.0, 'data use requirements, in this  <publication>  we present all subnational ', 0.005291005291005291, 1]
[1.0, 2.0, 871.0, 4.0, 'publication we present all subnational  <estimates>  excluding those pending See ', 0.005256241787122208, 1]
[1.0, 5.0, 882.0, 4.0, 'org/gbd-search For the online data  <visualisation>  tool see https://vizhub. healthdata.org/gbd-compare ', 0.005249343832020997, 1]
[1.0, 6.0, 885.0, 4.0, 'both sexes combined. The geographical  <variation>  in the leading Level ', 0.005249343832020997, 1]
[1.0, 53.0, 872.0, 4.0, 'geographies to estimate a prior  <distribution>  ', 0.005249343832020997, 1]
[1.0, 6.0, 894.0, 4.0, 'Level 3 causes of YLD  <rates>  across countries is shown: ', 0.005188067444876783, 1]
[1.0, 50.0, 873.0, 4.0, 'could cause a relatively small  <proportion>  of all anaemia cases, ', 0.0051813471502590676, 1]
[1.0, 51.0, 906.0, 4.0, 'terms of global age-standardised prevalence  <rates>  for both sexes in ', 0.005069708491761723, 1]
[1.0, 6.0, 922.0, 4.0, 'the leading cause of YLD  <rates>  in Mexico, Equatorial Guinea, ', 0.0050062578222778474, 1]
[1.0, 6.0, 953.0, 4.0, 'the leading cause of YLD  <rates>  in Yemen, India, Antigua ', 0.004819277108433735, 1]
[1.0, 42.0, 884.0, 4.0, 'of tuberculosis including latent tuberculosis  <infection>  increased by 26·2% (21·7 ', 0.0047169811320754715, 1]
[1.0, 42.0, 902.0, 4.0, 'of all-age and age-standardised YLD  <rates>  with SDI globally and ', 0.004618937644341801, 1]
[1.0, 42.0, 976.0, 4.0, 'a downwards gradient indicating a  <reduction>  in YLD rate. The ', 0.00425531914893617, 1]
[1.0, 66.0, 920.0, 8.0, 'grants and personal fees from  <AstraZeneca>  and Boehringer-Ingelheim and personal ', 0, 0]
[1.0, 53.0, 110.0, 6.0, 'GBD 2017 as opposed to  <separately>  estimating autism and Asperger’s ', 0, 0]
[1.0, 0.0, 100.0, 4.0, 'how the decline of mortality  <rates>  from 1990 to 2016 ', 0, 0]
[1.0, 0.0, 227.0, 4.0, 'of death models to inform  <estimates>  using a total of ', 0, 0]
[1.0, 0.0, 291.0, 4.0, 'of estimation, ensuring consistency between  <rates>  of incidence, prevalence, remission, ', 0, 0]
[1.0, 0.0, 319.0, 4.0, 'a disability weight for health  <states>  of each mutually exclusive ', 0, 0]
[1.0, 0.0, 375.0, 4.0, 'for Accurate and Transparent Health  <Estimates>  Reporting. Findings Globally, for ', 0, 0]
[1.0, 0.0, 474.0, 4.0, 'sexes combined. All-cause age-standardised YLD  <rates>  decreased by 3·9% (95% ', 0, 0]
[1.0, 0.0, 525.0, 4.0, 'with increases in all-age YLD  <rates>  of 7·9% (6·6–9·2) for ', 0, 0]
[1.0, 0.0, 549.0, 4.0, 'in terms of age-standardised prevalence  <estimates>  for multiple causes. The ', 0, 0]
[1.0, 0.0, 608.0, 4.0, 'Interpretation Global all-cause age-standardised YLD  <rates>  have improved only slightly ', 0, 0]
[1.0, 0.0, 717.0, 4.0, 'injury. Funding Bill & Melinda  <Gates>  Foundation.Lancet 2018; 392: 1789–858 ', 0, 0]
[1.0, 1.0, 121.0, 4.0, 'success in terms of diminishing  <rates>  of premature death but ', 0, 0]
[1.0, 3.0, 41.0, 4.0, 'main text (appendix 2). Subnational  <estimates>  for countries with populations ', 0, 0]
[1.0, 3.0, 70.0, 4.0, 'published elsewhere are presented wherever  <estimates>  are illustrated with maps ', 0, 0]
[1.0, 3.0, 86.0, 4.0, 'tables. Cause-specific results for non-fatal  <estimates>  for GBD 2017 cover ', 0, 0]
[1.0, 4.0, 65.0, 4.0, 'by providing incidence and prevalence  <estimates>  adjusted for read mission, ', 0, 0]
[1.0, 5.0, 120.0, 4.0, 'descriptions of all 234 health  <states>  used in the estimation ', 0, 0]
[1.0, 6.0, 28.0, 4.0, 'Table 1 reports cause-specific global  <estimates>  of prevalence, incidence, and ', 0, 0]
[1.0, 6.0, 56.0, 4.0, 'in YLDs and age-standardised YLD  <rates>  between 1990, 2007, and ', 0, 0]
[1.0, 6.0, 67.0, 4.0, '. Unless otherwise specified, all  <rates>  reported in this analysis ', 0, 0]
[1.0, 38.0, 16.0, 4.0, 'Level 3 causes of YLD  <rates>  by country and subnational ', 0, 0]
[1.0, 38.0, 148.0, 4.0, 'the top cause of YLD  <rates>  between 1990 and 2017 ', 0, 0]
[1.0, 39.0, 9.0, 4.0, 'Vol 392 November 10, 2018YLD  <rates>  as SDI increased (figure ', 0, 0]
[1.0, 39.0, 40.0, 4.0, 'showed an increase in YLD  <rates>  for more than a ', 0, 0]
[1.0, 39.0, 77.0, 4.0, 'or increases in age-standardised YLD  <rates>  over the past decade ', 0, 0]
[1.0, 40.0, 28.0, 4.0, 'deﬁciencyOther musculoskeletal disorders* 028056084011201400Age-standardised YLD  <rates>  per 100 000 people ', 0, 0]
[1.0, 42.0, 36.0, 4.0, '100 000 males. Figure 5A  <illustrates>  the differences in global ', 0, 0]
[1.0, 43.0, 1001.0, 4.0, 'Table 2: Global age-standardised prevalence  <rates>  per 100 000 for ', 0, 0]
[1.0, 47.0, 35.0, 4.0, 'and all age and age-standardised  <rates>  for each sex Causes ', 0, 0]
[1.0, 48.0, 245.0, 4.0, '1990 and 2007, age-standardised YLD  <rates>  for females decreased for ', 0, 0]
[1.0, 51.0, 50.0, 4.0, 'for both sexes, with sex-specific  <rates>  of 1012·8 YLDs (689·4–1436·5) ', 0, 0]
[1.0, 51.0, 72.0, 4.0, 'Globally, in terms of YLD  <rates>  in 2017, anaemia is ', 0, 0]
[1.0, 51.0, 117.0, 4.0, 'in terms of age-standardised YLD  <rates>  globally for females in ', 0, 0]
[1.0, 52.0, 139.0, 4.0, 'our inpatient admission per -capita  <estimates>  to include in- facility ', 0, 0]
[1.0, 53.0, 15.0, 4.0, 'disorders, although in future studies,  <estimates>  of neurological disorders will ', 0, 0]
[1.0, 54.0, 19.0, 4.0, 'cascade. Time trends in our  <estimates>  result from where the ', 0, 0]
[1.0, 54.0, 24.0, 4.0, 'estimates result from where the  <covariates>  are changing over time, ', 0, 0]
[1.0, 54.0, 121.0, 4.0, 'version of DisMod that explicitly  <incorporates>  a full age-time-period model ', 0, 0]
[1.0, 59.0, 724.0, 4.0, 'and Operational Research Project, Abt  <Associates>  Nepal, Lalitpur, Nepal (K ', 0, 0]
[1.0, 62.0, 402.0, 4.0, 'Affairs, Government of the Federated  <States>  of Micronesia, Palikir, Federated ', 0, 0]
[1.0, 62.0, 407.0, 4.0, 'States of Micronesia, Palikir, Federated  <States>  of Micronesia (S V ', 0, 0]
[1.0, 62.0, 695.0, 4.0, 'Smart University, Dubai, United Arab  <Emirates>  (Prof S Hamidi DrPH); ', 0, 0]
[1.0, 65.0, 652.0, 4.0, 'of Sharjah, Sharjah, United Arab  <Emirates>  (B Saddik PhD); Neurogenic ', 0, 0]
[1.0, 66.0, 301.0, 4.0, 'Dhabi, Abu Dhabi, United Arab  <Emirates>  (Prof E Tuzcu MD); ', 0, 0]
[1.0, 67.0, 196.0, 4.0, 'by the Bill & Melinda  <Gates>  Foundation, the University of ', 0, 0]
[1.0, 67.0, 552.0, 4.0, 'Evaluation, funded by the United  <States>  Agency for International Development ', 0, 0]
[1.0, 67.0, 847.0, 4.0, 'were supplied by the United  <States>  Renal Data System. The ', 0, 0]
[1.0, 67.0, 1078.0, 4.0, 'A comparison of maternal mortality  <estimates>  from GBD 2013 and ', 0, 0]
[1.0, 68.0, 128.0, 4.0, 'for accurate and transparent health  <estimates>  reporting: the GATHER statement. ', 0, 0]
[1.0, 56.0, 39.0, 4.0, 'Johnson, Jost B Jonas, Jacek  <Jerzy>  Jozwiak, Suresh Banayya Jungari, ', 0, 0]
[1.0, 0.0, 140.0, 68.0, 'substantial portion of the world’s  <population>  experiences non-fatal health loss ', 0, 0]
[1.0, 1.0, 21.0, 68.0, 'the most complex endeavours in  <population>  health research. The evolution ', 0, 0]
[1.0, 0.0, 694.0, 50.0, 'conditions have led to older  <populations>  with complex and potentially ', 0, 0]
[1.0, 2.0, 57.0, 50.0, 'disability (YLDs). Transitions in ageing  <populations>  and reduced mortality in ', 0, 0]
[1.0, 2.0, 110.0, 50.0, 'rapidly transform the burden in  <populations>  with access to these ', 0, 0]
[1.0, 3.0, 45.0, 50.0, 'Subnational estimates for countries with  <populations>  larger than 200 million ', 0, 0]
[1.0, 44.0, 95.0, 50.0, 'prevalent cases per 100 000  <populationA>  Females MalesAge (years) Age ', 0, 0]
[1.0, 44.0, 174.0, 50.0, 'in YLDs per 100 000  <populationB>  Females MalesAge (years) Age ', 0, 0]
[1.0, 57.0, 986.0, 18.0, 'G Tekalign MS); Department of  <Population>  and Family Health (K ', 0, 0]
[1.0, 59.0, 1323.0, 18.0, 'Department of Global Health and  <Population>  (Prof T W Bärnighausen ', 0, 0]
[1.0, 60.0, 351.0, 18.0, 'MD), Division of Patient and  <Population>  (Prof W Marcenes PhD), ', 0, 0]
[1.0, 60.0, 358.0, 18.0, 'W Marcenes PhD), School of  <Population>  Health & Environmental Sciences ', 0, 0]
[1.0, 61.0, 69.0, 18.0, 'R Chang MD); Institute of  <Population>  Health Sciences, National Health ', 0, 0]
[1.0, 61.0, 112.0, 18.0, '(A Chattopadhyay PhD), Department of  <Population>  Studies (A Patle MPH), ', 0, 0]
[1.0, 61.0, 135.0, 18.0, 'Ram PhD), International Institute for  <Population>  Sciences, Mumbai, India (S ', 0, 0]
[1.0, 61.0, 926.0, 18.0, '(K Dokova PhD); Department of  <Population>  and Health, University of ', 0, 0]
[1.0, 62.0, 567.0, 18.0, 'MD); Department of Epidemiology and  <Population>  Health (H Hosgood PhD), ', 0, 0]
[1.0, 62.0, 700.0, 18.0, 'Emirates (Prof S Hamidi DrPH);  <Population>  Health Department, University of ', 0, 0]
[1.0, 64.0, 208.0, 18.0, '(A Manda MD); Department of  <Population>  Studies, University of Zambia, ', 0, 0]
[1.0, 64.0, 427.0, 18.0, 'Peru Country Office, United Nations  <Population>  Fund (UNFPA), Lima, Peru ', 0, 0]
[1.0, 64.0, 798.0, 18.0, 'Werdecker PhD), Federal Institute for  <Population>  Research, Wiesbaden, Germany (Prof ', 0, 0]
[1.0, 64.0, 809.0, 18.0, 'O Mueller MD); Center for  <Population>  and Health, Wiesbaden, Germany ', 0, 0]
[1.0, 65.0, 252.0, 18.0, 'Delhi, India (A Patle MPH);  <Population>  Health Group (Prof G ', 0, 0]
[1.0, 65.0, 1058.0, 18.0, 'She MD); Usher Institute of  <Population>  Health Sciences and Informatics, ', 0, 0]
[1.0, 67.0, 288.0, 18.0, 'Demoscope together with the Carolina  <Population>  Center, University of North ', 0, 0]
[1.0, 67.0, 477.0, 18.0, 'should contact Add Health, Carolina  <Population>  Center, 123 W. Franklin ', 0, 0]
[1.0, 68.0, 140.0, 18.0, '388: e19–23. 21 United Nations  <Population>  Division. Department of Economic ', 0, 0]
[1.0, 68.0, 198.0, 18.0, '3: e712–23. 24 GBD 2017  <Population>  and Fertility Collaborators. P ', 0, 0]
[1.0, 68.0, 203.0, 16.0, 'Population and Fertility Collaborators. P  <opulation>  and fertility by age ', 0, 0]
[1.0, 24.0, 267.0, 10.0, '−9·9)*−2·5% (−3·9 to −1·0)* Atrial  <fibrillation>  and flutter 37 574·2 ', 0, 0]
[1.0, 39.0, 113.0, 10.0, 'in most regions, but this  <relation>  was less reliable for ', 0, 0]
[1.0, 68.0, 203.0, 10.0, 'Population and Fertility Collaborators. P  <opulation>  and fertility by age ', 0, 0]
[1.0, 68.0, 583.0, 10.0, 'American College of Cardiology Foundation.  <Circulation>  2011; 124: 2458–73. 38 ', 0, 0]
[1.0, 68.0, 621.0, 10.0, 'Task Force on Practice Guidelines.  <Circulation>  2014; 129: S76–99.39 Stone ', 0, 0]
[1.0, 68.0, 665.0, 10.0, 'Task Force on Practice Guidelines.  <Circulation>  2014; 129: S1–45. 40 ', 0, 0]
[1.0, 68.0, 911.0, 10.0, 'to new targets (TNT) study.  <Circulation>  2012; 125: 1979–87 . ', 0, 0]
[1.0, 22.0, 423.0, 7.0, '7·9)* Myelodysplastic, myeloproliferative, and other  <haemopoietic>  neoplasms1212·2 (1098·1 to 1332·1)134·3 ', 0, 0]
[1.0, 53.0, 43.0, 7.0, 'cause “myelodysplastic, myeloproliferative, and other  <haemopoietic>  neoplasms”, which were previously ', 0, 0]
[1.0, 73.0, 41.0, 5.0, 'Cada agrupación de productores estará  <relacionada>  con la estructura del ', 0, 0]
[1.0, 0.0, 136.0, 4.0, 'also shown how a substantial  <portion>  of the world’s population ', 0, 0]
[1.0, 0.0, 166.0, 4.0, 'include increasing the level of  <estimation>  detail, improving analytical strategies, ', 0, 0]
[1.0, 0.0, 422.0, 4.0, 'and tuberculosis including latent tuberculosis  <infection>  in both 1990 and ', 0, 0]
[1.0, 0.0, 603.0, 4.0, '(3265 [2943–3630] vs 5643 [5057–6302]).  <Interpretation>  Global all-cause age-standardised YLD ', 0, 0]
[1.0, 0.0, 724.0, 4.0, '2018; 392: 1789–858 This online  <publication>  has been corrected. The ', 0, 0]
[1.0, 1.0, 25.0, 4.0, 'in population health research. The  <evolution>  of modern health-care systems ', 0, 0]
[1.0, 1.0, 92.0, 4.0, 'necessitated continuous refinement as diagnostic  <classification>  systems expand, new diseases ', 0, 0]
[1.0, 3.0, 125.0, 4.0, 'is the first time that  <estimation>  of fertility and population ', 0, 0]
[1.0, 4.0, 78.0, 4.0, 'nosis, outpatient utilisation, or a  <combination>  of the above, but ', 0, 0]
[1.0, 4.0, 97.0, 4.0, 'remission rates, procedure rates, and  <distribution>  of disease subtypes. The ', 0, 0]
[1.0, 4.0, 108.0, 4.0, 'methods provide a more detailed  <description>  of how the clinical ', 0, 0]
[1.0, 5.0, 71.0, 4.0, 'the supplementary methods (appendix 1  <section>  4). Disability weight estimation ', 0, 0]
[1.0, 5.0, 75.0, 4.0, '1 section 4). Disability weight  <estimation>  is described in more ', 0, 0]
[1.0, 6.0, 123.0, 4.0, 'and tuberculosis including latent tuberculosis  <infection>  (1·93 billion, 1·71–2·20; table ', 0, 0]
[1.0, 7.0, 475.0, 4.0, '−9·4)*−4·2% (−6·5 to −1·8)* Chlamydial  <infection>  109 822·0 (93 827·4 ', 0, 0]
[1.0, 8.0, 303.0, 4.0, '(1·9 to 4·2)* Lower respiratory  <infection>  episode10 625·8 (9719·1 to ', 0, 0]
[1.0, 9.0, 116.0, 4.0, '−29·2)*−22·0% (−29·5 to −13·6)* Intestinal  <perforation>  due to paratyphoid6·7 (5·2 ', 0, 0]
[1.0, 11.0, 372.0, 4.0, '−8·0)*−13·3% (−17·1 to −9·4)* Acute  <infection>  due to other neglected ', 0, 0]
[1.0, 12.0, 67.0, 4.0, '−17·6)*−52·5% (−54·6 to −50·2)* Meningococcal  <infection>  1076·7 (764·8 to 1424·7)402·5 ', 0, 0]
[1.0, 13.0, 307.0, 4.0, 'Maternal sepsis and other maternal  <infection>  episode916·5 (511·3 to 1514·1)11 ', 0, 0]
[1.0, 14.0, 75.0, 4.0, 'Neonatal sepsis and other neonatal  <infection>  complications13 944·6 (8561·4 to ', 0, 0]
[1.0, 14.0, 105.0, 4.0, 'Neonatal sepsis and other neonatal  <infection>  episode323·9 (254·4 to 405·5)330·1 ', 0, 0]
[1.0, 23.0, 117.0, 4.0, '−10·7)*−6·4% (−7·6 to −5·1)* Myocardial  <infarction>  due to ischaemic heart ', 0, 0]
[1.0, 28.0, 41.0, 4.0, '2007–17 (Continued from previous page)  <Medication>  overuse headache due to ', 0, 0]
[1.0, 28.0, 139.0, 4.0, 'to −0·3)*0·3% (−0·1 to 0·6)  <Medication>  overuse headache due to ', 0, 0]
[1.0, 32.0, 537.0, 4.0, 'to 6·1)−3·7% (−5·3 to −2·1)*  <Refraction>  disorders 185 392·8 (165 ', 0, 0]
[1.0, 37.0, 163.0, 4.0, '−11·0)*3·4% (2·4 to 4·5)* Pulmonary  <aspiration>  and foreign body in ', 0, 0]
[1.0, 45.0, 238.0, 4.0, 'injuriesSelf-harm and interpersonal violence Improving  <DivergentWorseningDirection>  of overall trend Deviation ', 0, 0]
[1.0, 49.0, 209.0, 4.0, 'resources for treatment and continued  <prevention>  and treatment interventions to ', 0, 0]
[1.0, 50.0, 101.0, 4.0, 'lost human capital given the  <concentration>  of the burden in ', 0, 0]
[0.0, 0.0, 0.0, 0.0, '0', 0, 0]
[0.0, 0.0, 0.0, 0.0, '0', 0, 0]
[0.0, 0.0, 0.0, 0.0, '0', 0, 0]
[0.0, 0.0, 0.0, 0.0, '0', 0, 0]
[1.0, 54.0, 45.0, 4.0, 'different time periods lead to  <variation>  in the posterior estimates. ', 0, 0]
[1.0, 54.0, 69.0, 4.0, 'do not directly take into  <consideration>  prevalence in 30-year-olds in ', 0, 0]
[1.0, 54.0, 85.0, 4.0, 'in 2010. This is a  <limitation>  for some diseases with ', 0, 0]
[1.0, 55.0, 54.0, 4.0, 'findings should help to focus  <prevention>  and treatment efforts on ', 0, 0]
[1.0, 57.0, 355.0, 4.0, 'Institute for Health Metrics and  <Evaluation>  (S L James MD, ', 0, 0]
[1.0, 57.0, 880.0, 4.0, 'Department of Bioinformatics and Medical  <Education>  (E O Nsoesie PhD), ', 0, 0]
[1.0, 57.0, 1014.0, 4.0, 'Duken MSc), Department of Health  <Education>  & Behavioral Sciences (G ', 0, 0]
[1.0, 58.0, 87.0, 4.0, 'G Weldegwergs MSc), Department of  <Nutrition>  and Dietetics (M G ', 0, 0]
[1.0, 58.0, 351.0, 4.0, 'Centre for Health Research and  <Implementation>  (B De Courten PhD), ', 0, 0]
[1.0, 58.0, 367.0, 4.0, 'Centre of Cardiovascular Research and  <Education>  in Therapeutics (R Ofori-Asenso ', 0, 0]
[1.0, 58.0, 512.0, 4.0, '(K A Afanvi MD); Prefectoral  <Direction>  of the Health of ', 0, 0]
[1.0, 58.0, 615.0, 4.0, 'S Zodpey PhD), Public Health  <Foundation>  of India, Gurugram, India ', 0, 0]
[1.0, 58.0, 703.0, 4.0, 'Salimi PhD), Department of Health  <Education>  & Promotion (F Rajati ', 0, 0]
[1.0, 58.0, 705.0, 4.0, 'Department of Health Education &  <Promotion>  (F Rajati PhD), Environmental ', 0, 0]
[1.0, 58.0, 734.0, 4.0, 'Sadeghi PhD), Sports Medicine &  <Rehabilitation>  (M Shamsi PhD), Imam ', 0, 0]
[1.0, 58.0, 831.0, 4.0, 'S N Irvani MD), Safety  <Promotion>  and Injury Prevention Research ', 0, 0]
[1.0, 58.0, 834.0, 4.0, 'MD), Safety Promotion and Injury  <Prevention>  Research Center (N Jahanmehr ', 0, 0]
[1.0, 58.0, 1077.0, 4.0, 'Based Practice Center, Mayo Clinic  <Foundation>  for Medical Education and ', 0, 0]
[1.0, 59.0, 141.0, 4.0, 'Australia; Department of Public Health  <Nutrition>  (N Fentahun PhD), Department ', 0, 0]
[1.0, 59.0, 237.0, 4.0, 'the Health Industrial Complex and  <Innovation>  in Health (Prof D ', 0, 0]
[1.0, 59.0, 253.0, 4.0, 'and Noncommunicable Diseases and Health  <Promotion>  (A M Soares Filho ', 0, 0]
[1.0, 59.0, 455.0, 4.0, 'Department of Health Policy and  <Administration>  (C T Antonio MD), ', 0, 0]
[1.0, 59.0, 462.0, 4.0, 'T Antonio MD), Development and  <Communication>  Studies (E K Macarayan ', 0, 0]
[1.0, 59.0, 525.0, 4.0, '(K Ghasemi Falavarjani MD), Air  <Pollution>  Research Center (B Heibati ', 0, 0]
[1.0, 59.0, 718.0, 4.0, 'Canada (A Artaman PhD); Monitoring  <Evaluation>  and Operational Research Project, ', 0, 0]
[1.0, 59.0, 758.0, 4.0, 'Center for Clinical Global Health  <Education>  (S R Atre PhD), ', 0, 0]
[1.0, 60.0, 644.0, 4.0, 'Collaborating Centre for Public Health  <Education>  and Training (D L ', 0, 0]
[1.0, 60.0, 893.0, 4.0, '(Prof L C Brant PhD),  <Nutrition>  Department (Prof R M ', 0, 0]
[1.0, 60.0, 1057.0, 4.0, 'A M Briggs PhD), Health  <Information>  (H Elkout PhD), World ', 0, 0]
[1.0, 61.0, 17.0, 4.0, 'Centre for Suicide Research and  <Prevention>  (Prof P Yip PhD), ', 0, 0]
[1.0, 61.0, 311.0, 4.0, '(M Cirillo MD); Faculty of  <Education>  (D Collado-Mateo MSc), Institute ', 0, 0]
[1.0, 61.0, 403.0, 4.0, 'Centers for Disease Control and  <Prevention>  (CDC), Atlanta, GA, USA ', 0, 0]
[1.0, 61.0, 545.0, 4.0, 'Guy’s and St Thomas’ NHS  <Foundation>  Trust, London, UK; James ', 0, 0]
[1.0, 61.0, 568.0, 4.0, 'I Sutradhar MPH), Research and  <Evaluation>  Division (M Rahman PhD), ', 0, 0]
[1.0, 61.0, 678.0, 4.0, 'Institute for Suicide Research and  <Prevention>  (Prof D De Leo ', 0, 0]
[1.0, 61.0, 749.0, 4.0, 'MSc), Aksum University, Aksum, Ethiopia;  <Information>  Services Division (G M ', 0, 0]
[1.0, 61.0, 1062.0, 4.0, 'for Health Care Policy and  <Innovation>  (J R Ehrlich MD), ', 0, 0]
[1.0, 62.0, 96.0, 4.0, 'Lazarus PhD); Division of Human  <Nutrition>  and Health, Wageningen University ', 0, 0]
[1.0, 62.0, 827.0, 4.0, 'J M Haro MD); Health  <Education>  and Health Promotion Department, ', 0, 0]
[1.0, 62.0, 830.0, 4.0, 'MD); Health Education and Health  <Promotion>  Department, School of Public ', 0, 0]
[1.0, 62.0, 896.0, 4.0, 'Sweden (R Havmoeller PhD); International  <Foundation>  for Dermatology, London, UK ', 0, 0]
[1.0, 62.0, 1000.0, 4.0, 'Center for Translation Research and  <Implementation>  Science (G A Mensah ', 0, 0]
[1.0, 63.0, 252.0, 4.0, 'for Epidemiology, Helmholtz Centre for  <Infection>  Research, Braunschweig, Germany (A ', 0, 0]
[1.0, 63.0, 1023.0, 4.0, 'Post Graduate Institute of Medical  <Education>  and Research, Chandigarh, India; ', 0, 0]
[1.0, 64.0, 9.0, 4.0, '392 November 10, 2018 1853Service  <Foundation>  Trust (NHS), Liverpool, UK ', 0, 0]
[1.0, 64.0, 343.0, 4.0, 'Oncology, National Institute of Cancer  <Prevention>  and Research, Noida, India ', 0, 0]
[1.0, 64.0, 575.0, 4.0, 'M Mirrakhimov MD); Institute of  <Addiction>  Research, Frankfurt University of ', 0, 0]
[1.0, 64.0, 727.0, 4.0, 'Australian Centre for Health Services  <Innovation>  (R Pacella PhD), School ', 0, 0]
[1.0, 64.0, 735.0, 4.0, 'PhD), School of Exercise and  <Nutrition>  Sciences (Q G To ', 0, 0]
[1.0, 64.0, 829.0, 4.0, 'Institute of Post Graduate Medical  <Education>  & Research, Kolkata, India ', 0, 0]
[1.0, 64.0, 1213.0, 4.0, 'University of Social Welfare and  <Rehabilitation>  Sciences, Iran (M Noroozi ', 0, 0]
[1.0, 65.0, 73.0, 4.0, 'The Institute for Health Research  <Foundation>  Jiménez Díaz University Hospital, ', 0, 0]
[1.0, 65.0, 356.0, 4.0, 'Health Policy Research, Centre for  <Addiction>  and Mental Health, Toronto, ', 0, 0]
[1.0, 65.0, 559.0, 4.0, 'Australia (Prof S Resnikoff MD);  <Organization>  for the Prevention of ', 0, 0]
[1.0, 65.0, 562.0, 4.0, 'Resnikoff MD); Organization for the  <Prevention>  of Blindness, Paris, France ', 0, 0]
[1.0, 65.0, 657.0, 4.0, 'Emirates (B Saddik PhD); Neurogenic  <Inflammation>  Research Center (A Sahebkar ', 0, 0]
[1.0, 65.0, 795.0, 4.0, 'J Sanabria MD); Department of  <Nutrition>  and Preventive Medicine, Case ', 0, 0]
[1.0, 65.0, 816.0, 4.0, 'of Public Health, Regional Health  <Administration>  Do Norte I P, ', 0, 0]
[1.0, 65.0, 882.0, 4.0, 'India (M Satpathy PhD); Udyam-Global  <Association>  for Sustainable Development, Bhubaneswar, ', 0, 0]
[1.0, 65.0, 953.0, 4.0, 'PhD); Division of Epidemiology and  <Prevention>  of Chronic Noncommunicable Diseases, ', 0, 0]
[1.0, 66.0, 440.0, 4.0, 'Federal Research Institute for Health  <Organization>  and Informatics of the ', 0, 0]
[1.0, 66.0, 456.0, 4.0, 'K Vladimirov PhD); Department of  <Information>  and Internet Technologies, I ', 0, 0]
[1.0, 66.0, 478.0, 4.0, 'PhD); Department of Health Care  <Administration>  and Economy, National Research ', 0, 0]
[1.0, 66.0, 494.0, 4.0, 'Russia (Prof V Vlassov MD);  <Foundation>  University Medical College, Foundation ', 0, 0]
[1.0, 66.0, 498.0, 4.0, 'MD); Foundation University Medical College,  <Foundation>  University, Rawalpindi, Pakistan (Y ', 0, 0]
[1.0, 66.0, 770.0, 4.0, 'PhD); Noncommunicable Disease Control and  <Prevention>  Center, Chinese Center for ', 0, 0]
[1.0, 66.0, 820.0, 4.0, 'appendix 1 for more detailed  <information>  about individual authors’ contributions ', 0, 0]
[1.0, 66.0, 835.0, 4.0, 'the following categories: managing the  <estimation>  process; writing the first ', 0, 0]
[1.0, 66.0, 898.0, 4.0, 'managing the overall research enterprise.  <Declaration>  of interests Carl Abelardo ', 0, 0]
[1.0, 66.0, 952.0, 4.0, 'Union’s Horizon 2020 research and  <innovation>  programme under Marie Sklodowska-Curie ', 0, 0]
[1.0, 66.0, 1033.0, 4.0, 'Council and the National Heart  <Foundation>  of Australia. Panniyammakal Jeemon ', 0, 0]
[1.0, 67.0, 124.0, 4.0, 'committee of OMERACT, an international  <organisation>  that develops measures for ', 0, 0]
[1.0, 67.0, 188.0, 4.0, 'Acknowledgments Research reported in this  <publication>  was supported by the ', 0, 0]
[1.0, 67.0, 321.0, 4.0, 'international study carried out in  <collaboration>  with WHO/EURO. The international ', 0, 0]
[1.0, 67.0, 730.0, 4.0, 'methodological details. The SHARE data  <collection>  has been primarily funded ', 0, 0]
[1.0, 67.0, 765.0, 4.0, 'from the German Ministry of  <Education>  and Research, the Max ', 0, 0]
[1.0, 67.0, 852.0, 4.0, 'States Renal Data System. The  <interpretation>  and reporting of these ', 0, 0]
[1.0, 67.0, 876.0, 4.0, 'as an official policy or  <interpretation>  of the US Government. ', 0, 0]
[1.0, 68.0, 417.0, 4.0, 'Associations between age, cohort, and  <urbanization>  with Sbp and Dbp ', 0, 0]
[1.0, 68.0, 553.0, 4.0, 'RO, et al. AHA/ACCF secondary  <prevention>  and risk reduction therapy ', 0, 0]
[1.0, 68.0, 556.0, 4.0, 'AHA/ACCF secondary prevention and risk  <reduction>  therapy for patients with ', 0, 0]
[1.0, 68.0, 576.0, 4.0, 'from the American H eart  <Association>  and American College of ', 0, 0]
[1.0, 68.0, 615.0, 4.0, 'American College of Cardiology/American Heart  <Association>  Task Force on Practice ', 0, 0]
[1.0, 68.0, 659.0, 4.0, 'American College of Cardiology/American Heart  <Association>  Task Force on Practice ', 0, 0]
[1.0, 68.0, 684.0, 4.0, 'European Guidelines on cardiovascular disease  <prevention>  in clinical practice (version ', 0, 0]
[1.0, 68.0, 707.0, 4.0, 'Other Societies on Cardiovascular Disease  <Prevention>  in Clinical Practice (constituted ', 0, 0]
[1.0, 68.0, 747.0, 4.0, 'over time: results from the  <Resuscitation>  Outcomes Consortium (ROC). Resuscitation ', 0, 0]
[1.0, 68.0, 751.0, 4.0, 'the Resuscitation Outcomes Consortium (ROC).  <Resuscitation>  2015; 91: 108. 42 ', 0, 0]
[1.0, 68.0, 893.0, 4.0, 'of residual risk in secondary  <prevention>  patients treated with high- ', 0, 0]
[1.0, 68.0, 923.0, 4.0, 'JA, Capewell S. Mortality risk  <reduction>  associated with smoking cessation ', 0, 0]
[1.0, 68.0, 927.0, 4.0, 'risk reduction associated with smoking  <cessation>  in patients with coronary ', 0, 0]
[1.0, 68.0, 1081.0, 4.0, 'Does long-term oxygen therapy reduce  <hospitalisation>  in hypoxaemic chronic obstructive ', 0, 0]
[1.0, 69.0, 230.0, 4.0, 'Ruigrok ANV, et al. C  <ognition>  in males and females ', 0, 0]
[1.0, 71.0, 120.0, 4.0, 'of the most representative agricultural  <production>  systems in the region, ', 0, 0]
[1.0, 86.0, 58.0, 4.0, 'Farm types and their economic  <characterization>  in complex agro-ecosystems for ', 0, 0]
[1.0, 87.0, 116.0, 4.0, 'Q. (2019). A review of  <characterization>  approaches for smallholder farmers: ', 0, 0]
[1.0, 44.0, 95.0, 4.0, 'prevalent cases per 100 000  <populationA>  Females MalesAge (years) Age ', 0, 0]
